Prolactinoma is an estrogen-related tumor and leukemia-related protein 16 （LRP16） is correlated with the progression of estrogen-related tumors, but the regulatory mechanism between LRP16 and prolactinoma remain unc...Prolactinoma is an estrogen-related tumor and leukemia-related protein 16 （LRP16） is correlated with the progression of estrogen-related tumors, but the regulatory mechanism between LRP16 and prolactinoma remain unclear. This study demonstrates a variation in LRP16 with estrogen receptor a （ERa） in prolactinoma models and the up and downregulation effects of LRP16 on prolactin secretion of pituitary adenomas cells （GH3 cells）. In our study, 50 male SD rats （30-day-old） were randomly divided into five groups of 10 rats each. After 120 days of treatment,展开更多
The present study investigated the influence of anti-estrogen treatment （fulvestrant） on pituitary adenoma cell line GH3 biological activity, the estrogen receptor a pathway, the WnT pathway, and mechanisms of decre...The present study investigated the influence of anti-estrogen treatment （fulvestrant） on pituitary adenoma cell line GH3 biological activity, the estrogen receptor a pathway, the WnT pathway, and mechanisms of decreased Wnt inhibitory factor-1 expression in GH3 cells. Results showed that fulvestrant suppressed GH3 cell proliferation and reduced hormone secretion in a dose-dependent manner. Estrogen receptor a and Wnt4 expression decreased, but Wnt inhibitory factor-1 expression increased in a dose-dependent manner following fulvestrant treatment, and β-catenin expression remained unchanged. Inhibitors of DNA methylation and histone modification upregulated Wnt inhibitory factor-1 expression. Results suggested that fulvestrant suppressed biological activity of GH3 cells via the estrogen receptor a and Wnt pathways. These results suggested that decreased Wnt inhibitory factor-1 expression in GH3 cells played a role in epigenetic mechanisms. Anti-estrogen therapies could provide novel treatments for growth hormone adenomas.展开更多
基金financially supported by the National Natural Science Foundation of China and Hainan Province.[NSFC,Grant Nos.81570705 and 81270866NSFH,Grant No.20168353]
文摘Prolactinoma is an estrogen-related tumor and leukemia-related protein 16 （LRP16） is correlated with the progression of estrogen-related tumors, but the regulatory mechanism between LRP16 and prolactinoma remain unclear. This study demonstrates a variation in LRP16 with estrogen receptor a （ERa） in prolactinoma models and the up and downregulation effects of LRP16 on prolactin secretion of pituitary adenomas cells （GH3 cells）. In our study, 50 male SD rats （30-day-old） were randomly divided into five groups of 10 rats each. After 120 days of treatment,
基金supported by the National Natural Science Foundation of China, No. 81072075
文摘The present study investigated the influence of anti-estrogen treatment （fulvestrant） on pituitary adenoma cell line GH3 biological activity, the estrogen receptor a pathway, the WnT pathway, and mechanisms of decreased Wnt inhibitory factor-1 expression in GH3 cells. Results showed that fulvestrant suppressed GH3 cell proliferation and reduced hormone secretion in a dose-dependent manner. Estrogen receptor a and Wnt4 expression decreased, but Wnt inhibitory factor-1 expression increased in a dose-dependent manner following fulvestrant treatment, and β-catenin expression remained unchanged. Inhibitors of DNA methylation and histone modification upregulated Wnt inhibitory factor-1 expression. Results suggested that fulvestrant suppressed biological activity of GH3 cells via the estrogen receptor a and Wnt pathways. These results suggested that decreased Wnt inhibitory factor-1 expression in GH3 cells played a role in epigenetic mechanisms. Anti-estrogen therapies could provide novel treatments for growth hormone adenomas.
